Kyle Moran Form 3 Wave Life Sciences / Kyle Moran ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Moran Kyle

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES LTD.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MA 02138

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
12/05/2020

3. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences Ltd. [ WVE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	20,084(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(2)	03/10/2025	Ordinary Shares	35,930	2.48	D
Share Option (Right to Buy)	(3)	06/16/2026	Ordinary Shares	21,647	18.79	D
Share Option (Right to Buy)	(4)	01/23/2028	Ordinary Shares	15,000	40.05	D
Share Option (Right to Buy)	(5)	03/03/2030	Ordinary Shares	36,000	8.17	D

Explanation of Responses:

1. Consists of 8,609 ordinary shares; 2,100 restricted share units (RSUs) that vest in four equal annual installments beginning on February 1, 2018 through February 1, 2021; 3,750 RSUs that vest in four equal annual installments of 25% beginning on February 15, 2019 through February 15, 2022; and 5,625 RSUs that vest in four equal annual installments of 25% beginning on February 15, 2020 through February 15, 2023.

2. The option vests as to 25% of the shares on July 1, 2015 and vests as to an additional 2.0833% of the shares monthly thereafter until July 1, 2018.

3. The option vests as to 25% of the shares on June 16, 2017 and vests as to an additional 2.0833% of the shares quarterly thereafter until June 16, 2020.

4. The option vests as to 25% of the shares on February 15, 2019 and vests as to an additional 6.25% of the shares quarterly thereafter until February 15, 2022.

5. The option vests as to 50% of the shares on February 1, 2021 and 50% on February 1, 2022.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Kyle Moran	12/11/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.